Quelling the Swelling and Ditching the Itching:
Ocular Anti-Inflammatory and Allergy Medications (Marquette A-B, Level 5)
Knowledge-type Activity
112-000-12-123-L01-P & 112-000-12-823-L01-T, 1.3 contact hours
Dean L. Luplow, OD, Michigan College of Optometry, Ferris State University, Big Rapids, Mich.
At the end of this presentation, participants should be able to discuss the pathophysiological mechanisms of ocular inflammation and ocular allergy; recall basic pharmacological terminology and concepts as they apply to the eye and basic pharmacodynamics of treatment of ocular inflammation and allergy; and identify the various classes of ocular anti-inflammatory and allergy medications and the specific drugs within each class.

Innovations in Community Practice:
Travel Medicine for the Community Pharmacist (LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-124-L01-P & 112-000-12-824-L01-T, 1.3 contact hours
Stephanie A. Klepser, Pharm.D., pharmacist - travel medicine, MSU/KCMS Pharmacy, Kalamazoo, Mich.
At the end of this presentation, participants should be able to describe the services a pharmacist can provide to the international traveler; discuss symptoms of various travel-related diseases, including vector-borne diseases and traveler’s diarrhea; outline a strategy for conducting a risk-based assessment of the international traveler; and recognize populations of travelers that may require special travel precautions to prevent illness.

Update in the Treatment of Lupus (Brule A-B, Level 5)
Application-type Activity
112-000-12-125-L01-P & 112-000-12-825-L01-T, 1.3 contact hours
Allison C. Bernknopf, Pharm.D., associate professor, Ferris State University College of Pharmacy, Kalamazoo, Mich.
At the end of this presentation, participants should be able to determine the most appropriate therapeutic option to treat systemic lupus erythematosus and related complications and identify medications that can lead to drug-induced lupus, given a patient case. Participants should also be able to identify medications currently in the pipeline for the treatment of systemic lupus erythematosus and related complications.

Medication Safety Considerations in Pain Management
(Ambassador Ballrooms 2-3, Level 3)
Knowledge-type Activity
112-000-12-126-L04-P & 112-000-12-826-L04-T, 1.3 contact hours
Mary E. Burkhardt, R.Ph., medication safety consultant, Medication Safety Solutions, Belleville, Mich.
At the end of this presentation, participants should be able to describe three common medication safety issues occurring nationally with pain management medications; describe three strategies to reduce patient harm with the use of pain medications; and discuss the strengths and weaknesses of various strategies used to reduce patient harm based on the “hierarchy of actions” concept. (This program meets requirements for obtaining pain management continuing education credit for pharmacists.)

Keynote Session:
Anticipating Health Information Technology’s Evolving Impact
(Ambassador Ballrooms 2-3, Level 3)
Knowledge-type Activity
112-000-12-127-L04-P & 112-000-12-827-L04-T,
1.0 contact hour
Timothy A. Pletcher, executive director, Michigan Health Information Network, Mt. Pleasant, Mich.
At the end of this presentation, participants should be able to provide an overview of the current United States health information technology landscape; identify the stages of “meaningful use” and their future bearing on pharmacists; describe semantic interoperability and its impact on the health care system; and discuss potential industry changes the next levels of health information sharing might enable.

Immunization/Vaccination Update (Marquette A-B, Level 5)
Application-type Activity
112-000-12-128-L01-P & 112-000-12-828-L01-T, 1.3 contact hours
Dean A. Van Loo, Pharm.D., associate professor, Ferris State University College of Pharmacy and Bronson Methodist Hospital, Kalamazoo, Mich.
At the end of this presentation, participants should be able to describe concerns and contemporary controversies of vaccine-preventable diseases; assess the need for vaccinations, given a patient; and make recommendations for vaccine dosing based on the most recent evidence.

 

Medication Therapy Management Services:
From Theory to Practice (LaSalle A-B, Level 5)
Application-type Activity
112-000-12-129-L04-P & 112-000-12-829-L04-T, 1.3 contact hours
Cathleen M. Edick, Pharm.D., clinical care coordinator, Spartan Stores, Mason, Mich.; and Lisa M. Meny, Pharm.D., assistant professor of pharmacy practice, Ferris State University College of Pharmacy, Grand Rapids, Mich.
At the end of this presentation, participants should be able to describe the key components to an effective medication therapy management (MTM) session; critique a MTM session; and identify the various types of MTM interventions available.

 

Management of Hepatitis C Virus Infection: Advancements and Challenges
(Cadillac A-B, Level 5)
Application-type Activity
112-000-12-130-L01-P & 112-000-12-830-L01-T, 1.3 contact hours
Stephanie L. Freed, Pharm.D., specialty pharmacy practice resident, Diplomat Specialty Pharmacy, Flint, Mich.; and Jennifer K. Hagerman, Pharm.D., AE-C, director of education, Diplomat Specialty Pharmacy, and adjunct faculty, Ferris State University College of Pharmacy, Flint, Mich.
At the end of this presentation, participants should be able to describe the etiology, clinical presentation and disease course of hepatitis C virus (HCV) infection; and differentiate between the available treatment options for a patient with chronic HCV infection and apply patient-specific treatment strategies. Participants should also be able to outline appropriate monitoring parameters for patients receiving treatment for HCV infection; apply strategies to manage adverse effects in patients receiving medications for treatment of HCV infection; and effectively counsel a patient with HCV infection.

 

Practical and Applied Ethics for the Practice of Pharmacy
(Ambassador Ballrooms 2-3, Level 3)
Knowledge-type Activity
112-000-12-131-L04-P & 112-000-12-831-L04-T, 1.3 contact hours
Jesse C. Vivian, R.Ph., JD, professor, Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Mich.
At the end of this presentation, participants should be able to identify the major principles of ethics encountered in health care delivery; recognize some of the more unethical situations encountered in pharmacy practice; and identify an ethics dilemma technique for solving problems.

Successful Curriculum Vitae Writing and Interviewing Skills
(Ambassador Ballroom 1, Level 3)
Knowledge-type Activity
112-000-12-151-L04-P & 112-000-12-851-L04-T, 1.3 contact hours
Kelly McNorton, Pharm.D., clinical specialist of critical care, St. John Hospital and Medical Center, Detroit, Mich.
At the end of this presentation, participants should be able to discuss key components of a curriculum vitae; identify techniques to a successful interview; recognize and prepare for important interview questions; and recall curriculum vitae writing and interviewing skills for future employment opportunities.

Home Infusion Basics (Marquette A-B, Level 5)
Knowledge-type Activity
112-000-12-132-L01-P & 112-000-12-832-L01-T, 1.3 contact hours
Christopher J. Maksym, Pharm.D., director, U of M Home Care Services, Dexter, Mich.; and Karen Miron, R.Ph., former pharmacy manager, Walgreens OptionCare Home Infusion, Grand Rapids, Mich.
At the end of this presentation, participants should be able to recognize home infusion terminology; identify which patients are good candidates for home infusion; discuss vascular access devices and delivery options; and discuss patient and family concerns and educational needs.

Viral Hepatitis (LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-133-L01-P & 112-000-12-833-L01-T, 1.3 contact hours
Michael E. Klepser, Pharm.D., professor of pharmacy, Ferris State University College of Pharmacy, Kalamazoo, Mich.
At the end of this presentation, participants should be able to describe the epidemiology of viral hepatitis; identify various antiviral agents with respect to their indications, efficacy and adverse event profiles; and identify potential side effects associated with antivirals used to treat patients with viral hepatitis.

 

Universal Precautions in Opiate Prescribing (Cadillac A-B, Level 5)
Knowledge-type Activity
112-000-12-134-L04-P & 112-000-12-834-L04-T, 1.3 contact hours
Mark Clark, MD, Javery Pain Institute, Grand Rapids, Mich.
At the end of this presentation, participants should be able to discuss risk assessment when prescribing opiates; explain the advantages of utilizing urine drug testing and the Michigan Automated Prescription System; and recognize the need for due diligence when prescribing opiates for chronic noncancer pain.

NASPA-NMA Student Pharmacist Self-care Championship
(Ambassador Ballrooms 2-3, Level 3)
Application-type Activity
112-000-12-135-L01-P & 112-000-12-835-L01-T, 1.3 contact hours
Participants to be determined Student pharmacists representing each college of pharmacy participate in a Jeopardy-like competition testing their knowledge of over-the-counter products. The program becomes interactive when student pharmacists use their “ask the audience” lifelines if they become stumped. This program is aimed at pharmacists, student pharmacists and pharmacy technicians. Come support your college of pharmacy and see who wins the traveling trophy this year. At the end of this presentation, participants should be able to identify and explain aspects of the effective and safe practice of pharmacy self-care treatments; analyze the usage and effectiveness of over-the-counter medications; and classify different groups of over-the-counter medications based on drug treatment class.

Pro/Con Debate: Tight Glycemic Control in the Critically Ill – How Low Should You Go? (Marquette A-B, Level 5)
Knowledge-type Activity
112-000-12-136-L01-P & 112-000-12-836-L01-T, 1.3 contact hours
Cesar Alaniz, Pharm.D., clinical associate professor of pharmacy, department of clinical sciences, University of Michigan College of Pharmacy, Ann Arbor, Mich.; and Simona O. Butler, Pharm.D., clinical pharmacist in critical care and clinical assistant professor, University of Michigan College of Pharmacy, Ann Arbor, Mich.
At the end of this presentation, participants should be able to define tight glycemic control as it applies to the critically ill; discuss limitations and risks of tight glycemic control; and summarize the evidence supporting tight glycemic control use in the setting of critical illness.

Transitions of Care – Patient Challenges
and Community Solutions (LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-137-L04-P & 112-000-12-837-L04-T, 1.3 contact hours
Mary Ellen Benzik, MD, Mercy Community Physicians, Battle Creek, Mich.
At the end of this presentation, participants should be able to articulate three challenges associated with patient transitions of care; describe at least three key pillars in a safe transition of care; and describe two community strategies to address the challenges of transitions.

 

Health Professional Recovery Program –
Protecting the Public, Saving Lives, Saving Careers (Cadillac A-B, Level 5)
Knowledge-type Activity
112-000-12-138-L04-P & 112-000-12-838-L04-T, 1.3 contact hours
Susan M. Bushong, health professional recovery program contract administrator and outreach coordinator, Michigan Department of Community Health, Bureau of Health Professions, Lansing, Mich.
At the end of this presentation, participants should be able to discuss resources for licensed health care professionals with substance abuse and/or mental health disorders, which may impair their ability to safely practice in their profession; recognize that health care professionals may require treatment; discuss mandatory reporting requirements; and examine content of the recovery monitoring agreement and when a participant may return to their profession.

How Pharmacies Fit Into the Patient-Centered Medical Home
(Brule A-B, Level 5)
Knowledge-type Activity
112-000-12-139-L04-P & 112-000-12-839-L04-T, 1.3 contact hours
Hae Mi Choe, Pharm.D., clinical associate professor, University of Michigan College of Pharmacy, Ann Arbor, Mich.; Heather L. Christensen, Pharm.D., director of pharmacy services, Spectrum Health United Memorial, Greenville, Mich.; Natalie Pirkola, Pharm.D., clinical pharmacist, Administrative Network, Inc. and Oakland Southfield Physicians, PC, Warren, Mich.; and Christopher Smith, R.Ph., pharmacy services manager, Spartan Stores, Ada, Mich.
At the end of this presentation, participants should be able to describe the patient-centered medical home (PCMH) model; identify opportunities within the practice sites for pharmacist involvement and interaction; and discuss reimbursement strategies for practicing within the PCMH. Participants should also be able to identify resources and references to utilize for PCMH practices; and describe the rules and regulations that pertain to practice in the PCMH.

Smart Financial Decisions (Nicolet A-B, Level 5)
Continuing education credit will not be awarded for this program.
Reuben Levinsohn, director of life and wealth solutions for medical professionals, Centennial Group, Lansing, Mich.
At the end of this presentation, participants should be able to develop a solid foundation that will act as a safety net for future investments; discuss how to implement time-tested investment strategies as you navigate an uncertain financial climate; and develop an investment plan to play the “tax game” more efficiently.

The Medication Safety Imperative (LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-140-L04-P & 112-000-12-840-L04-T, 1.3 contact hours
Timothy Arnold, Pharm.D, clinical pharmacist in medication safety inpatient pharmacy, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, Mich.; and Mary E. Burkhardt, R.Ph., medication safety consultant, Medication Safety Solutions, Belleville, Mich.
At the end of this presentation, participants should be able to state the importance of medication safety in patient care; list three tools or strategies used to improve medication safety; define high-alert medications and list five agents that meet this definition; discuss resources available to pharmacists and pharmacy technicians for information about medication safety; and discuss the conceptual differences between safety and quality.

Is it a Valid Prescription? (Cadillac A-B, Level 5)
Knowledge-type Activity
112-000-12-141-L03-P & 112-000-12-841-L03-T, 1.3 contact hours
Rosalie M. Baran, R.Ph., assistant professor of pharmacy, Ferris State University College of Pharmacy, Haslett, Mich.
At the end of this presentation, participants should be able to identify valid verbal, faxed, paper and electronic prescriptions; describe the differences between the Michigan and federal Drug Enforcement Administration (DEA) requirements related to electronically transmitted prescriptions; identify what a valid prescription is, as it relates to prescriber signatures, transfers and out-of-state prescribers; and describe the DEA’s definition of “agent” and how it may affect the validity of a prescription. (This program meets pharmacy law requirements for certified pharmacy technicians.)

MTM: Patient Safety, Quality Measures
and the Role of the Pharmacist (Marquette A-B, Level 5)
Knowledge-type Activity
112-000-12-142-L04-P & 112-000-12-842-L04-T, 1.3 contact hours
Dan Rodriguez, director of provider services, Outcomes Pharmaceutical Health Care, West Des Moines, Iowa
At the end of this presentation, participants should be able to recognize categories of patient safety issues related to medication use; explain HEDIS Measures/STAR Ratings as emerging quality metrics; discuss the evolution of medication therapy management (MTM) services within Medicare Part D and other health care payers; and outline the framework for engaging local pharmacists in identifying patient safety issues through the delivery of MTM services.

 

Use of Inhaled Antifungals in Immunocompromised Patients
(Nicolet A-B, Level 5)
Knowledge-type Activity
112-000-12-143-L01-P & 112-000-12-843-L01-T, 1.3 contact hours
Michael E. Klepser, Pharm.D., professor of pharmacy, Ferris State University College of Pharmacy, Kalamazoo, Mich.
At the end of this presentation, participants should be able to summarize technical requirements for aerosolization of an antifungal; identify patients for whom use of an inhaled antifungal may be appropriate; and outline an evidencebased approach to the use of inhaled antifungals.